Spending on CBD- and cannabis-related lobbying in the US exceeded pre-pandemic numbers, with more than $12m spent during the first quarter of 2022 on issues such as efforts to support patient safety, legalisation, decriminalisation, and providing a proper framework for interstate commerce.